- Bioasis Technologies Inc. (TSXV:BTI) has announced positive results from a preclinical study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor in multiple sclerosis rodent models
- Previous work determined that a recombinant fusion protein of the company’s proprietary xB3 peptide with an interleukin-1 receptor (xB3 IL-1RA) showed efficient delivery of effective concentrations of IL-1RA to the brain which elicited analgesia in a neuropathic animal model
- The study confirms the potential of xB3 IL-1RA to treat neuroinflammatory diseases like multiple sclerosis
- Shares of Bioasis Technologies are unchanged at C$0.38 as of 3:40 p.m. EDT
Bioasis Technologies (BTI) has announced results from its preclinical study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor.
The New Haven, Connecticut-based company is developing its proprietary xB3 platform technology in order to boost the delivery of biologics across the blood-brain barrier to treat central nervous system disorders that have high unmet medical needs.
According to the release, the company’s interleukin-1 receptor antagonist previously demonstrated efficient delivery of effective concentrations of IL-1RA to the brain, which elicited analgesia in a neuropathic pain animal.
xB3 IL-1RA was also investigated in the rodent experimental allergic encephalomyelitis (EAE) model of multiple sclerosis.
A range of doses of xB3 IL-1RA was given during the initial disease phase, which led to both delayed onset and overall a reduction in clinical symptom score in animals treated with xB3 IL-1RA compared to control animals.
“These data further confirm the ability of the xB3™ delivery platform to enhance the delivery of large molecule therapeutics into CNS compartments with demonstrated disease-relevant efficacy,” Dr. Deborah Rathjen, executive chair of the board at Bioasis Technologies, said in a release. “We are progressing these data and believe that xB3™-IL-1RA holds promise for the treatment of a broad range of neuroinflammatory diseases.”
Data from the study also indicates that xB3 IL-1RA has the potential to treat neuroinflammatory diseases like multiple sclerosis.
On a global scale, approximately 1.25 billion are affected by a neurological disease, with that number projected to continue rising.
Bioasis Technologies is one such company focused on developing therapies across the blood-brain barrier, which will essentially target previously untreatable diseases of the central nervous system.
Shares of Bioasis Technologies are unchanged at C$0.38 as of 3:40 p.m. EDT.
